BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IMGN-151 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IMGN-151\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05527184-11142@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:IMGN-151: Phase 1 readout est. (NCT05527184)
DESCRIPTION:IMGN-151\, phase 1\, Endometrial Cancer.\nStudy: First in Human
  Study of IMGN151 in Recurrent Gynaecological Cancers\nEstimated primary c
 ompletion: February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/imgn-151#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05527184
URL:https://assetmemo.bio/drug/imgn-151#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024784-11142@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:IMGN-151: Phase 2 readout est. (NCT07024784)
DESCRIPTION:IMGN-151\, phase 2.\nStudy: A Study to Assess Change in Disease
  Activity and Adverse Events in Adult Participants With Gynecologic Cancer
 s Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combinati
 on With Other Therapies\nEstimated primary completion: January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/imgn-151#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07024784
URL:https://assetmemo.bio/drug/imgn-151#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
